INTRODUCTION
Heparan sulphate proteoglycans (HSPGs) and heparin are known to have an number of important functions (reviewed in ref. [1] ), such as providing the non-thrombogenic nature of the endothelial glycocalyx [2] [3] [4] [5] and serving as the receptor for tissue-synthesized lipoprotein lipase on endothelial cell layers where it is active in plasma lipoprotein triacylglycerol hydrolysis [6] [7] [8] [9] [10] . More recently it has become clear that the HSPGs and heparin also play roles in signalling pathways. For example, they serve as reservoirs of growth factors by protecting them from proteolytic degradation [11] [12] [13] , and cell-surface HSPGs (or mixed chondroitin sulphate/heparan sulphate proteoglycans) act as growth factor receptors [14] [15] [16] [17] [18] [19] [20] .
Some specific signalling involves heparin/heparan sulphatebinding sites. Heparin and endothelial HSPGs inhibit the growth and migration of vascular smooth-muscle cells [21, 22] , presumably by binding to the approx. 105 specific heparin/heparan sulphate-binding sites/cell [23] . Heparin binding to smoothmuscle results in synthetic changes [24] [25] [26] [27] [28] . Heparin also binds to endothelial cells [29] [30] [31] [32] , where its binding leads to changes in synthesis of extracellular matrix protein [33] and causes an increase in secreted HSPGs, and possibly other HSPG changes as well [34] [35] [36] . Binding studies with human umbilical-vein endothelial cells indicate between 106 [31] and 107 [29] binding sites/cell. Direct evidence indicates internalization of cell-bound heparin in endothelial cells [30, 32] . Although the intracellular location of the heparin has not been identified in endothelial cells, some of the internalized heparin is known to go to the nucleus in HeLa cells [25] and hepatocytes [37, 38] . Cultured porcine endothelial cells retain a heparin-releasable HSPG population on their surfaces which is presumably associated with the heparin/heparan sulphate-binding sites [39] . Heparin and heparan sulphate also modulate endothelial cell grown by a mechanism that might involve their interaction with growth factors [40] .
Examples of other stimuli which cause changes in endothelialfrom detergent-solubilized endothelial cells. The heparin-binding protein isolated from porcine aortic endothelial cells using four different monoclonal antibodies has an M, of 45000 assessed by SDS/PAGE. The 45 000-Mr heparin-binding polypeptide is isolated as a multimer. The antibody-isolated protein binds to heparin-affinity columns as does the pure 45 000-Mr polypeptide, consistent with its identification as a putative endothelial heparin receptor.
cell HSPG synthesis that may involve heparin/heparan sulphate receptors include the following. (1) Extracellular matrix removal or vessel injury induces endothelial cells to proliferate and synthesize a new matrix including sulphated proteoglycans [41] .
(2) Wounding of cultured endothelial cells leads to an alteration in the synthesis of radiolabelled proteoglycans which localize in the cell layer [42] . (3) Cultured bovine endothelial cells increase the percentage of radiolabelled proteoglycan incorporated into their extracellular matrix after reaching confluence [43] . (4) Growth of endothelial cells on HSPG-depleted matrix results in higher levels of HSPG synthesis compared with growth on normal matrix [44] . In vitro changes in endothelial HSPG synthesis may serve as clues to similar changes that occur in disease situations. In atherosclerosis, the endothelial extracellular matrix may contain less HSPG than the original matrix [45] [46] [47] . Changes in the amount and type of endothelial-layer glycosaminoglycans that accumulate during the disease process are proposed to be involved in the build-up of lipid in the atherosclerotic plaque [45, [47] [48] . Vascular complications of diabetes also include altered patterns of endothelial HSPG synthesis in the affected blood vessels [49] [50] [51] [52] [53] .
Despite significant progress in understanding heparin involvement in signalling, the involvement of a heparin receptor(s) and its mechanism(s) remain unclear. The identification of a heparin receptor is critical to understanding the receptor-mediated aspects of heparin signalling. The identity of a specific endothelial heparin-binding protein, which is therefore a putative receptor, is the subject of the present report. 
EXPERIMENTAL

Cell culture
The isolation and maintenance of porcine aortic endothelial (PAE) cells have been described previously [34, 39, 54] . Briefly, cells were grown at 37°C with 5 % CO2 on gelatin-coated dishes in Dulbecco's modified Eagle's medium with 10 % heatinactivated serum and antibiotics as reported. When the cells had become established, they were weaned into 10 % heat-inactivated Serum Plus (JRH Biosciences, Hazelton Biologics, Lenexa, KS, U.S.A.) by using a 50: 50 mixture of heat-inactivated serum and heat-inactivated Serum Plus for one passage. For preparation of radiolabelled putative heparin receptor, PAE cells were labelled with [35S]methionine at 2,Ci/ml in normal growth medium. After 48 h, the cells were harvested by removal of media, washing with PBS, scraping and pelleting of the cells in PBS, and solubilization of the pellets in PBS with 0.2% CHAPS to solubilize the cell membranes and protease inhibitors. Removal of cell debris was accomplished with a low-speed spin (2000 g) before further analysis.
Hybridoma production and culture
Female Balb/c mice (10 weeks old) from Jackson Laboratories were immunized with 2.5 x 106 endothelial cells in Freund's complete adjuvant by subcutaneous injection into the abdomen. Booster injections of about 2.5 x 106 cells in PBS were given every 2.5-4.5 weeks. Antibodies to whole endothelial cells (determined by ELISA [55] with whole endothelial cells grown on multiwell plates) were observed after two or three booster injections. Fusions were accomplished essentially as described [55] using the murine myeloma cell line P3X63-Ag8653 obtained from a subculture used by Stamatoglou and Keller [56] originally from the Institute of Medical Research (Camden, NJ, U.S.A.). Poly(ethylene glycol) was used to stimulate cell fusion. The hybridoma cells were grown in 96-well plates with hypoxanthine/ amethopterin/thymidine (HAT) medium as described [55] to select against myeloma cell survival. The medium was a 1: 1 mixture of the above medium and Swiss mouse 3T3 cellconditioned medium (containing 20% rather than 10% heatinactivated fetal bovine serum). For long-term hybridoma cultivation, HAT was removed from the medium, and the serum 
Isolation of antibody and putative heparin receptor
The antibodies produced by the hybridoma cells were separated from other protein components of the hybridoma supernatants using affinity chromatography on 1 ml columns of anti-mouse IgG-agarose at 4 'C, with monitoring of column flow at A280. The hybridoma supernatants were passed twice over the columns and then washed extensively with PBS until baseline was maintained. The antibodies were eluted from the affinity resin with glycine (0.1 M, pH 2.5) and neutralized with Tris/HCl buffer, pH 9.0, or 0.1 M NaHCO3. In some experiments, tubes used for antibody collection were coated with carrier protein (immunoassay-grade BSA).
The radiolabelled solubilized PAE cells, prepared as described above were mixed 1:1 (v/v) with purified antibodies [between 5 and 30 jug of antibody, 18H6, 18E9, 12B1, 18B6, 18C4, anti-(LH receptor) or non-immune IgG] and allowed to bind for 48 h at 4 'C. The antibody/cell extract was passed over a 2 ml affinity column of Protein G-Sepharose at 4 'C in the same buffer as was used for cell solubilization. Loading buffer was used to wash the column until there was no protein or radioactivity in the eluted fractions. Glycine (0.1 M, pH 2.5, with 0.2 % CHAPS) was used to disrupt the antibody interaction with the affinity column. The eluted sample was dripped into Tris/HCl buffer, pH 9.0, (or 0.1 M NaHCO3) with 0.2 % CHAPS for neutralization. Protease inhibitors (50 ,uM e-aminocaproic acid, 5 mM benzamidine, 2 mM N-ethylmaleimide and 1 mM PMSF) were included in the incubation mixtures which did not contain carrier albumin.
One alternative isolation using antibody supernatant and antimouse IgG columns involved mixing the cells 1:2 (v/v) with antibody 18H6 and binding to anti-mouse IgG-agarose in the same buffer as above. In this procedure, 4 M urea in PBS with 0.2% CHAPS was employed to elute the radiolabelled sample from the affinity column. The urea-elution protocol resulted in trapping of some radiolabelled protein in the column. Therefore reduced to 15 % in non-conditioned medium. most isolations were routinely accomplished as described above using glycine to disrupt the antibody-resin interactions.
Biotinylatlon of cell-surface proteins
Biotinylation of cell-surface proteins was carried out with whole cells and the water-soluble biotinylation reagent NHS-LC-Biotin. The reaction was carried out essentially as recommended by the supplier. NHS-LC-Biotin (final concentration 1 mM in PBS) was added to 150 mm-diameter dishes of confluent cells, which had been carefully washed with PBS (pH 7.5) to remove excess amines from the culture medium. The cells were incubated at 25°C for 30 min. The reaction was stopped by removing the biotin solution, and any remaining biotin quenched with PBS containing 50 mM Tris/HCl (final pH 7.8) and 0.01 % BSA). The cells were washed three times with the same solution before receptor preparation as above for radiolabelled samples. Typically one plate of cells was used for each experiment, and a second identical plate for a non-immune mouse IgG control. Protease inhibitors (50 ,M e-aminocaproic acid, 5 mM benzamidine, 2 mM N-ethylmaleimide, and 1 mM PMSF) were included in the incubations of biotinylated proteins and antibodies.
Analytical technique Chromatography columns (1 cm x 100 cm) were packed with Sepharose CL4B, CL6B and Sephacryl S-300. The columns were equilibrated in CHAPS buffer (0.1 M Tris/HCl, pH 6.5, 0.1 % CHAPS, 1 mM EDTA, 1 mM PMSF) or CHAPS buffer with 2 M urea at 4°C as indicated. Some columns were also run in 0.2 % CHAPS or 0.2 % octyl fl-D-glucopyranoside instead of 0.1 % CHAPS. Fractions of 1.8 ml each were collected, and aliquots of each fraction were analysed by scintillation counting. All sizing columns were calibrated using BSA and ovalbumin.
fl-Galactosidase and alcohol dehydrogenase were also employed in the calibration of CL4B columns. Protein elution was determined by monitoring A280.
Heparin-affinity column chromagraphy employed 0.5 cm x 15 cm columns of heparin-Sepharose in the CHAPS column buffer noted above at 4 'C. Radiolabelled proteins were applied to the affinity column and the column was washed with CHAPS column buffer. Elution of radiolabelled proteins was by batch with 100 ,ug/ml heparin in CHAPS buffer followed by 2 M urea in CHAPS buffer. Alternatively, bound material was eluted with a 100 ml linear gradient of 0-2 M NaCl in CHAPS buffer. In the gradient elution, 1.8 ml fractions were collected and monitored for A280 and radioactivity. SDS/PAGE was accomplished using the Laemmli technique [57] . Samples with radioactive protein were prepared by mixing with SDS sample buffer, concentration in Amicon centricons, incubation at 55 'C for 20 min and dialysis against SDS sample buffer; they were then boiled for 5 min before loading on the gel. Gels were stained with Coomassie Brilliant Blue, and individual lanes cut into 2 mm slices. The slices were either oxidized using H202 Figure 3 in which antibody 18H6 was used). However, the non-specific bands that showed up in both samples varied from experiment to experiment. When blots from experiments with identical quantities of control and specific blocking antibodies were analysed by densitometric scanning, the blocking antibody samples had at least ten-fold more absorbance at Mr 45000 than samples isolated with an identical amount of non-immune mouse IgG. In most experiments there was no absorbance in the 45 000Mr region of the non-immune samples.
Analysis of intact putative receptor by gel filtration
In order to obtain evidence for the intact putative heparin receptor structure, antibody-radiolabelled putative heparin The 450004Mr polypeptide from the urea elution of an anti-mouse IgG affinity column isolation described in the text was analysed by SDS/PAGE. The gel was analysed by scintillation counting of 2 mm slices as described in the Experimental section.
binding heparin, its ability to bind to heparin-Sepharose affinity columns was determined. When the 35S-radiolabelled antibodyputative heparin receptor mixtures were warmed to 37°C for 20 min to facilitate antibody exchange and diluted 1:1 with cold column buffer to decrease reassociation, % of the radiolabelled protein bound to heparin-Sepharose affinity columns. Elution of bound material with a salt gradient resulted in a number of peaks of radioactivity starting somewhat before 0.5 M NaCl ( Figure 5 The 45000-Mr polypeptide analysed in Figure 6 was also analysed by heparin-affinity chromatography as described in the Experimental section. The NaCI gradient began at fraction 1 and ended at fraction 72. Entire fractions were analysed for radioactivity. The dotted line indicates the salt gradient.
NaCl. This basic profile was observed with putative heparin receptor isolated using antibodies 18E9 and 18B6, although differences in peak height were noted.
Identfflcation of the putative receptor by an alternative affinity isolation The alternative isolation protocol using anti-mouse IgG resin and 4 M urea to elute any antibody-putative receptor complex resulted in loss of some radiolabelled protein on the column (although antibodies were eluted). Attempts to recover the 35S-radiolabelled putative heparin receptor for the anti-mouse IgG affinity columns involved batch washing the resin with 4 M urea. This resulted in a preparation of protein which migrated on SDS/identically with the 45000-M, putative heparin receptor polypeptide ( Figure 6 ). This 45 000-Mr polypeptide also bound to heparin-Sepharose, and was eluted with a gradient of NaCl (Figure 7) . The elution produced a single peak at just above 0.5 M NaCi. The peak aligns with the central region of the antibody-putative heparin receptor chromatographic elution shown in Figure 5 .
DISCUSSION
Despite evidence of heparin binding to endothelial cells [29, 31] and heparin-induced changes in endothelial-cell HSPG synthesis [34] [35] [36] , identification of a specific heparin receptor in endothelial cells has not been forthcoming. Previous attempts to isolate a heparin-binding protein from PAE cell plasma membranes using heparin-affinity chromatography have been frustrated by the number of proteins that bind to heparin. A recent publication [59] indicates that a very large number of heparin-binding proteins can be identified from epithelial cells when specific heparin affinity of membrane proteins is the criterion employed. Growth factors [11] [12] [13] 40] , antithrombin III [3] , extracellular matrix proteins (reviewed ref. in [60] ) and platelet/endothelialcell adhesion molecule [61] are among those proteins known to interact with heparin. The topic of heparin interaction with proteins has been extensively reviewed [1] . Heparin-affinity chromatography has also been used to purify-proteins that may interact with the affinity matrix based on ion-exchange mechanisms or the ability of heparin to act as a nucleic acid analogue (e.g. restriction endonucleases as in ref. [62] ).
Evidence obtained by binding of radiolabelled heparin to endothelial cells suggests between 106 [31] and 107 [29] binding sites per cell. Therefore, to obtain a specific method for identifying putative heparin-receptor proteins, monoclonal antibodies were produced against whole PAE cells. As such a receptor should be among the PAE cell-surface proteins, the hybridomas produced were screened for their ability to produce antibodies that would inhibit the binding of heparin to confluent PAE cells. Nine such hybridomas were identified. The use of confluent cells resulted in low binding of heparin to extracellular matrix. Platelet/ endothelial-cell adhesion molecule 1 and other cell adhesion molecules are primarily localized at cell-cell junctions in confluent cells [63] and are probably also unavailable for heparin binding. Therefore antibodies against extracellular matrix proteins or cell adhesion molecules would not be likely to inhibit a significant portion of heparin binding to the confluent cells.
Although the variability for non-blocking antibodies in a single experiment was around 20 % of the average (see Figure 1) , some variability in the heparin-binding assay was expected as a result of differences, including the amount of antibody, between the hybridoma supernatants. Differences in [3H]heparin (between different shipments), PAE cell line and cell age might also contribute to variability between assays. Regardless of the variability between experiments, the reproducibility within each experiment indicates differences between the blocking antibodies and other hybridoma supernatants. Many of the experiments resulted in no identification of blocking antibodies, again indicating that the variability between non-blocking antibodies was low enough to allow recognition of blocking antibodies rather than simple selection of the hybridoma supernatants with the lowest heparin binding from each experiment. The decision to select hybridomas that significantly inhibited heparin binding biased the selection of antibodies towards those recognizing a protein responsible for a significant portion of heparin binding to endothelial cells. Heparin-binding proteins accounting for a low percentage of PAE cell heparin binding would not be identified by this procedure.
Despite variability between the antibody-identification experiments, the values of percentage inhibition by the four antibodies used for protein isolation in this report were quite similar. Although there may be differences in affinity or epitope recognized, the data from the identification experiments suggest that the four antibodies act on the same heparin-binding site, a fact substantiated by the isolation of the same polypeptide by all four antibodies. The inhibition of radiolabelled heparin binding by unlabelled heparin is typically in the same range as the inhibition by these antibodies, suggesting that they act at the primary endothelial heparin-binding site.
The antibody inhibition of heparin binding to the cell surface indicates a cell-surface location for the binding interactions. The biotin labelling of the antibody-isolated putative heparin receptor is further evidence for the cell-surface location of this protein. Activated biotin-containing molecules have been used to label a number of cell-surface proteins in whole cells [64] . The NHS-LCBiotin used in the present studies was chosen for its water solubility, which would facilitate labelling of whole cells in physiological buffers and make internalization of the biotin very unlikely.
Anti-mouse IgG-agarose-purified antibodies from the supernatants of four of the hybridomas that blocked heparin binding Figure 2(a) indicate that an IgM antibody Protein G alone) supports the identification of this putative heparin receptor as a protein responsible for heparin binding to endothelial cells. The ability of the isolated protein to bind to heparin-affinity columns is further support for the identification. The complex elution of the radioactive putative receptorantibody mixtures from the heparin column may be due to the antibodies remaining in the sample, the lipid component associated with the antibody-putative heparin receptor mixture, the presence of different mutimeric forms, or any combination of these factors. Pure 45000-M, protein (without antibodies) is eluted from heparin-affinity columns with a single peak and small shoulder (Figure 7) which align with the central region of the antibody-putative heparin receptor chromatographic elution ( Figure 5 ). This result is consistent with any of the above explanations proposed for elution of the antibody-putative receptor mixture.
Elution of the putative heparin receptor for the heparinaffinity matrix at around 0.5 M NaCl suggests that heparin binding would occur in physiological salt concentrations. Although some other heparin-binding proteins (e.g. growth factors) bind heparin much more tightly than the putative heparin receptor, the dissociation constants reported for heparin binding to endothelial cells [29, 30] are in the micromolar range, suggesting that these sites bind heparin less tightly than growth factors (most of which have dissociation constants in the picomolar range). Furthermore, heparin-induced changes in endothelial cell behaviour occur at heparin concentrations too high to be due only to such high-affinity heparin-binding molecules. In fact, such high-affinity sites might be constantly saturated by endogenous heparan sulphate from one or more of the many endothelial-cell-surface HSPGs [65, 66] .
Endothelial cells bind heparin [29] [30] [31] , and saturation of the PAE cell heparin-binding sites results in a change in HSPG synthesis [34] [35] [36] . Heparin also modulates endothelial synthesis of extracellular matrix proteins [33] . Responses to heparin binding in a number of cell types include heparin internalization [30] and transport to the nucleus [25, 37, 38] , changes in gene expression [24] [25] [26] [27] and inhibition of cell growth [21, 22] . Such heparin-induced alterations in cell behaviour may require specific heparin-receptor activity. Although many proteins bind to heparin, the specific protein(s) responsible for mediating heparin effects in cells has not previously been identified.
The heparin responses in endothelial cells may be due to the putative heparin receptor identified in the present report. The identification of a candidate heparin receptor from endothelial cells provides the opportunity to determine whether it plays a role in the control of HSPG synthesis. Significant additional work will be necessary to establish the function(s) of this putative heparin receptor. Antibodies that block heparin binding to endothelial cells through the putative heparin receptor should be useful in determining the involvement of the protein in heparin signalling.
